News headlines about Spark Therapeutics (NASDAQ:ONCE) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Spark Therapeutics earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.3423833117505 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern’s rankings:
- Analyzing Medivation (MDVN) and Spark Therapeutics (ONCE) (americanbankingnews.com)
- Spark Therapeutics (ONCE) Downgraded by UBS to “Neutral” (americanbankingnews.com)
- Spark Therapeutics (ONCE) Downgraded to “Market Perform” at Leerink Swann (americanbankingnews.com)
- Spark Therapeutics Inc (ONCE) Expected to Post Quarterly Sales of $9.53 Million (americanbankingnews.com)
- -$1.74 Earnings Per Share Expected for Spark Therapeutics Inc (ONCE) This Quarter (americanbankingnews.com)
Spark Therapeutics (NASDAQ ONCE) opened at $49.05 on Tuesday. Spark Therapeutics has a 1 year low of $41.06 and a 1 year high of $91.75.
A number of research firms have commented on ONCE. Cantor Fitzgerald restated a “buy” rating on shares of Spark Therapeutics in a research report on Friday, August 25th. BidaskClub upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, August 26th. Barclays assumed coverage on shares of Spark Therapeutics in a report on Wednesday, September 6th. They issued an “overweight” rating and a $104.00 target price on the stock. Royal Bank of Canada assumed coverage on shares of Spark Therapeutics in a report on Thursday, September 14th. They set an “outperform” rating and a $100.00 price target on the stock. Finally, SunTrust Banks restated a “buy” rating and set a $95.00 price target (up previously from $85.00) on shares of Spark Therapeutics in a report on Monday, September 25th. Two analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $76.19.
In other news, CFO Stephen W. Webster sold 10,000 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $70.14, for a total value of $701,400.00. Following the completion of the sale, the chief financial officer now directly owns 12,500 shares in the company, valued at $876,750. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Katherine A. High sold 5,000 shares of the business’s stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total transaction of $356,600.00. Following the completion of the sale, the insider now owns 215,000 shares of the company’s stock, valued at $15,333,800. The disclosure for this sale can be found here. Insiders sold 1,067,309 shares of company stock valued at $89,681,885 over the last three months. Insiders own 7.30% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.com-unik.info/2017/12/19/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-spark-therapeutics-once-share-price.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.